VERSARTIS
Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix. Headquartered in Redwood City, California, Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The compan... y is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner. The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.
VERSARTIS
Social Links:
Industry:
Biotechnology Health Care Therapeutics
Founded:
2008-12-01
Address:
Menlo Park, California, United States
Country:
United States
Website Url:
http://www.versartis.co
Total Employee:
1+
Status:
Closed
Contact:
16509638598
Email Addresses:
[email protected]
Total Funding:
279.5 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Nginx DoubleClick.Net CloudFront Google Adsense AdBlock Acceptable Ads Google Adsense For Domains SEO_H1
Similar Organizations
Affini-T Therapeutics
Affini-T Therapeutics is a biotechnology company developing T-cell therapies for patients suffering from cancer.
Alios BioPharma
Alios BioPharma is a biotechnology company developing novel medicines for the treatment of viral diseases.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
Living Proof
Living Proof is a biotechnology company developing product formulae to solve beautycare problems.
Milestone Pharmaceuticals
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
ORGANIC GENOMICS
ORGANIC GENOMICS is a biotechnology company for developing health care products of therapeutic proteins.
Sanguistat
Sanguistat is a biotechnology company that develops approaches to the treatment of bleeding disorders.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
New Leaf Venture Partners
New Leaf Venture Partners investment in Series E - Versartis
Aisling Capital
Aisling Capital investment in Series E - Versartis
Advent Life Sciences
Advent Life Sciences investment in Series E - Versartis
Sofinnova Investments
Sofinnova Investments investment in Series E - Versartis
Amunix
Amunix investment in Series D - Versartis
New Leaf Venture Partners
New Leaf Venture Partners investment in Series D - Versartis
Sofinnova Investments
Sofinnova Investments investment in Series D - Versartis
Aisling Capital
Aisling Capital investment in Series D - Versartis
Advent Venture Partners
Advent Venture Partners investment in Series D - Versartis
Index Ventures
Index Ventures investment in Series D - Versartis
Official Site Inspections
http://www.versartis.co
- Host name: 38.114.101.30
- IP address: 38.114.101.30
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Versartis"
Versartis - Crunchbase Company Profile & Funding
Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension …See details»
VERSARTIS INC. Company Profile | Palo Alto, CA | Competitors ...
Find company research, competitor information, contact details & financial data for VERSARTIS INC. of Palo Alto, CA. Get the latest business insights from Dun & Bradstreet.See details»
Versartis Inc - LinkedIn
Versartis, Inc. is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS …See details»
Versartis Company Profile 2024: Valuation, Investors ... - PitchBook
Developer of recombinant human growth hormones dedicated to transforming treatments for patients with endocrine disorders.See details»
Versartis, Inc. (VSAR) company profile and facts - Yahoo Finance
See the company profile for Versartis, Inc. (VSAR), including business summary, industry/sector information, number of employees, corporate governance, key executives and salary information.See details»
Versartis, Inc.: Drug pipelines, Patents, Clinical trials - Synapse
Explore Versartis, Inc. with its drug pipeline, therapeutic area, technology platform, 12 clinical trials, 10 news, and 1 literature.See details»
Versartis - Funding, Financials, Valuation & Investors - Crunchbase
Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders.See details»
Versartis - Products, Competitors, Financials, Employees, …
Versartis is a biopharmaceutical company focused on developing endocrine therapies. Its main product is a long-acting form of recombinant human growth hormone designed for the …See details»
Versartis | EquityNet
Versartis, Inc. is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. The company was founded in December 2008 as a joint venture between …See details»
Versartis - Overview, News & Similar companies | ZoomInfo.com
Versartis contact info: Phone number: (650) 963-8580 Website: www.versartis.com What does Versartis do? The Company is initially developing somavaratan (VRS-317), its novel long …See details»
Versartis - Crunchbase
Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders.See details»
Versartis Enters into Merger Agreement with Aravive
Jun 4, 2018 · Aravive Biologics is a privately held clinical stage biopharmaceutical company developing novel, highly selective therapies designed to treat serious cancers and certain …See details»
Behind the Brand with Versartis - YouTube
Versartis, Inc. is an endocrine-focused biopharmaceutical company initially developing novel, long-acting recombinant human growth hormone for the treatment ...See details»
Versartis Inc. - The New York Times
BusinessSee details»
Versartis grabs $126M in an upsized IPO to fund its orphan drug
Mar 21, 2014 · With its combined $181 million, Versartis plans to pay its way through a Phase III study for VRS-317, a long-acting recombinant human growth hormone designed to treat HGH …See details»
Versartis - Contacts, Employees, Board Members, Advisors & Alumni
Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders.See details»
Versartis: Could This Be A Successful Turnaround In The Making?
Jun 15, 2018 · In all, we recommend Versartis as a speculative Buy and have raised its rating to three out of five stars. And we expect the price target of $4.00 to be reached in six months.See details»
Versartis Careers and Employment | Indeed.com
Mar 4, 2019 · Find out what works well at Versartis from the people who know best. Get the inside scoop on jobs, salaries, top office locations, and CEO insights. Compare pay for popular roles …See details»
Versartis - Preparing To Get A Lot Bigger, Very Soon - Seeking Alpha
Versartis is preparing to present phase 3 trial data on its lead compound in the coming months. Current investor concerns include neutralizing antibodies observed in Phase 2 as well as...See details»
Karl Trass - Vice President, Regulatory Affairs @ Versartis ...
His experience encompasses building and leading organizational units including regulatory, quality assurance, safety, and manufacturing; managing development and commercial …See details»